Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting IRGQ for antitumor immunity in HCC

BC Staff
January 28, 2025 12:37 AM UTC

Targeting IRGQ, an autophagy receptor that promotes lysosomal degradation and autophagy of misfolded MHC class I molecules, could help treat hepatocellular carcinoma (HCC) by increasing tumor antigen presentation and subsequent antitumor immunity.

Proteomics analyses in a human pancreatic cancer cell line with and without functional autophagy identified IRGQ as an autophagy receptor. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Goethe University Frankfurt